Neurodegenerative Diseases
Conditions
Brief summary
This study aims to investigate whether biomarkers of Alzheimer's disease can be found in tearfluid, as well as dried bloodspots in patients with Alzheimer's disease, other dementia diagnoses compared to controls.
Detailed description
Participants under investigation of a neurodegenerative disease who have a planned lumbar puncture in the Memory clinic will be invited to this study. On the same day of the lumbar puncture, tear fluid and dry blod spots will be collected. Tear fluid is collected using Shirmer's test. Dried blood spots are obtained by a small prick in the finger with a lancet. The blood droplet is transferred onto a special piece of filter paper, where it dries. As a sub-study, participants who have provided written consent specifically for this purpose will repeat the test with dried blood spots at home one week after participating in the study. The samples are submitted to the Memory Clinic at the participant's next scheduled appointment. Tear fluid, dried blood spots, as well as blood and cerebrospinal fluid will be examined for AD-related pathology.
Interventions
None listed
Sponsors
Danish Dementia Research Centre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for patients: * Lumbar puncture with CSF avaiable for analysis * Diagnosis of Alzheimer's disease, Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) or Normal pressure hydrocephalus (NPH) * Of legal age. Inclusion criteria for controls: * Lumbar puncture with CSF avaiable for analysis * No neurological disease. * Of legal age.
Exclusion criteria
* No lumbar puncture * Clinically assessed as unfit to participate in the project.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AD related biomarkers in tear fluid | Two years | Concentrations of AD biomarkers (AB42, AB40, Ptau217, NfL, GFAP) in tear fluid in the AD-group compared to non-AD and controls. |
| AD related biomarkers in dry blod spots | Two years | Concentrations of AD biomarkers (AB42, AB40, Ptau217, NfL, GFAP) in dry blot spots in the AD-group compared to non-AD and controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Testing dry blod spots at home | Two years | To test the feasability of dry blod spots card in a home setting - measuring concentrations of AD biomarkers in the blod cards performed at home compared to the card performed in the clinic. |
Countries
Denmark
Contacts
Primary ContactSteen G Hasselbalch, DMSc
Outcome results
None listed